RA Capital Management’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.35B | Hold |
10,281,496
| – | – | 24.92% | 1 |
|
|
2025
Q4 | $2.19B | Hold |
10,281,496
| – | – | 22.46% | 1 |
|
|
2025
Q3 | $2.04B | Hold |
10,281,496
| – | – | 25.19% | 1 |
|
|
2025
Q2 | $1.77B | Hold |
10,281,496
| – | – | 29.9% | 1 |
|
|
2025
Q1 | $1.6B | Buy |
10,281,496
+168,752
| +2% | +$24.1M | 26.76% | 1 |
|
|
2024
Q4 | $1.39B | Buy |
10,112,744
+402,316
| +4% | +$52.9M | 18.53% | 1 |
|
|
2024
Q3 | $1.45B | Sell |
9,710,428
-397,972
| -4% | -$53.7M | 16.72% | 1 |
|
|
2024
Q2 | $1.38B | Hold |
10,108,400
| – | – | 18.23% | 1 |
|
|
2024
Q1 | $1.53B | Buy |
10,108,400
+1,000
| +0% | +$143K | 19.44% | 1 |
|
|
2023
Q4 | $1.27B | Sell |
10,107,400
-612,155
| -6% | -$61M | 19.88% | 1 |
|
|
2023
Q3 | $1B | Sell |
10,719,555
-505,802
| -5% | -$47.3M | 19.76% | 1 |
|
|
2023
Q2 | $1B | Buy |
11,225,357
+4,268,178
| +61% | +$371M | 18.92% | 1 |
|
|
2023
Q1 | $746M | Hold |
6,957,179
| – | – | 16.89% | 1 |
|
|
2022
Q4 | $850M | Sell |
6,957,179
-610,721
| -8% | -$70.9M | 17.23% | 1 |
|
|
2022
Q3 | $781M | Hold |
7,567,900
| – | – | 16.67% | 1 |
|
|
2022
Q2 | $704M | Hold |
7,567,900
| – | – | 18.76% | 1 |
|
|
2022
Q1 | $888M | Hold |
7,567,900
| – | – | 19.38% | 1 |
|
|
2021
Q4 | $1.02B | Buy |
7,567,900
+180,000
| +2% | +$26.8M | 17.95% | 1 |
|
|
2021
Q3 | $1.18B | Buy |
7,387,900
+581,559
| +9% | +$79.6M | 16.32% | 1 |
|
|
2021
Q2 | $895M | Buy |
6,806,341
+394,113
| +6% | +$52.5M | 14.37% | 1 |
|
|
2021
Q1 | $826M | Buy |
6,412,228
+546,890
| +9% | +$83.1M | 12.46% | 1 |
|
|
2020
Q4 | $978M | Sell |
5,865,338
-44,404
| -0.8% | -$7.34M | 13.67% | 1 |
|
|
2020
Q3 | $912M | Buy |
5,909,742
+994,787
| +20% | +$143M | 16.68% | 1 |
|
|
2020
Q2 | $727M | Hold |
4,914,955
| – | – | 14.17% | 1 |
|
|
2020
Q1 | $553M | Buy |
4,914,955
+729,613
| +17% | +$94.8M | 17.48% | 1 |
|
|
2019
Q4 | $582M | Buy |
4,185,342
+52,900
| +1% | +$5.88M | 17.66% | 2 |
|
|
2019
Q3 | $398M | Hold |
4,132,442
| – | – | 23.72% | 1 |
|
|
2019
Q2 | $476M | Hold |
4,132,442
| – | – | 25.54% | 1 |
|
|
2019
Q1 | $486M | Sell |
4,132,442
-108,094
| -3% | -$9.47M | 20.97% | 1 |
|
|
2018
Q4 | $266M | Hold |
4,240,536
| – | – | 15.46% | 2 |
|
|
2018
Q3 | $300M | Hold |
4,240,536
| – | – | 16.06% | 2 |
|
|
2018
Q2 | $282M | Hold |
4,240,536
| – | – | 18.31% | 2 |
|
|
2018
Q1 | $277M | Sell |
4,240,536
-1,340,154
| -24% | -$75.3M | 21.25% | 2 |
|
|
2017
Q4 | $224M | Hold |
5,580,690
| – | – | 18.71% | 2 |
|
|
2017
Q3 | $202M | Hold |
5,580,690
| – | – | 18.28% | 1 |
|
|
2017
Q2 | $155M | Buy |
5,580,690
+170,700
| +3% | +$4.51M | 17.78% | 1 |
|
|
2017
Q1 | $151M | Hold |
5,409,990
| – | – | 18.58% | 2 |
|
|
2016
Q4 | $109M | Buy |
5,409,990
+1,728,499
| +47% | +$34.5M | 15.51% | 2 |
|
|
2016
Q3 | $74M | Buy |
3,681,491
+268,634
| +8% | +$4.43M | 7.63% | 3 |
|
|
2016
Q2 | $45.3M | Buy |
3,412,857
+1,251,491
| +58% | +$19.3M | 6.27% | 7 |
|
|
2016
Q1 | $40.1M | Buy |
2,161,366
+489,919
| +29% | +$8.7M | 5.12% | 6 |
|
|
2015
Q4 | $30.6M | Buy |
1,671,447
+210,179
| +14% | +$3.68M | 3.03% | 9 |
|
|
2015
Q3 | $25.9M | Sell |
1,461,268
-451,885
| -24% | -$8.8M | 3.71% | 8 |
|
|
2015
Q2 | $33.8M | Buy |
1,913,153
+889,501
| +87% | +$15.6M | 3.4% | 10 |
|
|
2015
Q1 | $17.8M | Buy |
+1,023,652
| New | +$18.6M | 1.76% | 17 |
|
Other funds holding ASND
ACA
PA
RA Capital Management's ASND Position: Q1 2026 in Review
RA Capital Management held its Ascendis Pharma A/S (ASND) position steady in Q1 2026 at 10,281,496 shares worth $2.35B. The position accounts for 24.92% of the portfolio, ranked #1.
RA Capital Management first reported a position in ASND in Q1 2015 and has held it in 45 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.
- RA Capital Management held 10,281,496 shares of Ascendis Pharma A/S worth $2.35B as of Q1 2026.
- RA Capital Management left its Ascendis Pharma A/S share count unchanged in Q1 2026.
- Ascendis Pharma A/S made up 24.92% of RA Capital Management's portfolio in Q1 2026, its #1 holding.
- RA Capital Management first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 45 quarters since.
- 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.
Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.